SCHEMBL15564697

SCHEMBL15564697

O=C(N[C@@H]1CCCc2ccccc21)C1Cc2ccccc2CN1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.55
ALDH1A1 P00352 5/20 0.54
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
EPHX1 P07099 1/20 0.53
CYP2D6 P10635 3/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
P2RX7 Q99572 1/20 0.52
TAS1R3 Q7RTX0 3/20 0.51
TAS1R1 Q7RTX1 3/20 0.51
TAS1R2 Q8TE23 3/20 0.51
LMNA P02545 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
HPGD P15428 1/20 0.50
TSHR P16473 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15564695 1.00 HTT (0.55) HTTALDH1A1KMT2AMEN1EPHX1
SCHEMBL18569491 1.00 HTT (0.55) HTTALDH1A1KMT2AMEN1EPHX1
SCHEMBL29857359 1.00 HTT (0.55) HTTALDH1A1KMT2AMEN1EPHX1
SCHEMBL31709770 1.00 HTT (0.55) HTTALDH1A1KMT2AMEN1EPHX1
Hydrochloric Acid SCHEMBL29892567 0.99 HTT (0.54) HTTALDH1A1KMT2AMEN1EPHX1
SCHEMBL16254377 0.90 TAS1R3 (0.55) HTTALDH1A1KMT2AMEN1EPHX1
SCHEMBL18173820 0.90 TAS1R3 (0.55) HTTALDH1A1KMT2AMEN1EPHX1
SCHEMBL22906909 0.90 TAS1R3 (0.55) HTTALDH1A1KMT2AMEN1EPHX1
SCHEMBL18173818 0.90 TAS1R3 (0.55) HTTALDH1A1KMT2AMEN1EPHX1
SCHEMBL16252351 0.90 TAS1R3 (0.55) HTTALDH1A1KMT2AMEN1EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2882740-B1 IAP ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2017-03-01 EP disclosed
US-9453048-B2 IAP antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2016-09-27 US disclosed
US-9453048-B2 IAP antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2016-09-27 US disclosed
US-20150225452-A1 IAP ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY 2015-08-13 US disclosed
US-20150225452-A1 IAP ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY 2015-08-13 US disclosed
EP-2882740-A1 IAP ANTAGONISTS Bristol-Myers Squibb Company (US) 2015-06-17 EP disclosed
WO-2014025759-A1 IAP ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225452-A1 IAP ANTAGONISTS XIAP, API5, BIRC5 HTT 3265/4885ALDH1A1 3456/4885KMT2A 4432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.